Showing 6211-6220 of 10817 results for "".
- LIBERTY-CSU CUPID-C: Improved Itch in Spontaneous Chronic Urticaria with Dupliumabhttps://practicaldermatology.com/news/liberty-csu-cupid-c-improved-itch-in-spontaneous-chronic-urticaria-with-dupliumab/2485781/Dupilumab significantly reduced itch and hives severity in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite histamine 1–receptor antagonist (H1-AH) therapy, according to results from the phase 3 LIBERTY-CSU CUPID-C trial published
- Economic Analysis Shows Wide Range in Annual Sunscreen Expenseshttps://practicaldermatology.com/news/economic-analysis-shows-wide-range-in-annual-sunscreen-expenses/2485778/A new 2025 economic evaluation of annual sunscreen costs found wide variation depending on unit pricing and clothing coverage. Investigators conducted the analysis from July through August 2025, modeling the cost of sunscreen
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://practicaldermatology.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve
- TOGETHER-PsO: Combination Therapy Links Obesity Treatment to Psoriasis Clearancehttps://practicaldermatology.com/news/together-pso-trial-links-obesity-treatment-to-enhanced-psoriasis-clearance/2485716/New data show that a combination therapy of ixekizumab (Taltz) plus tirzepatide (Zepbound) was superior to ixekizumab alone for achieving PASI 100 and ≥10% weight loss at 36 weeks in adults with moderate-to-severe plaque psoriasis. The phase 3b TOGETHER-PsO
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful
- South Beach Symposium: Dr. Neal Neal Bhatia Maps a Fragmented but Promising Pipelinehttps://practicaldermatology.com/news/south-beach-symposium-dr-neal-neal-bhatia-maps-a-fragmented-but-promising-pipeline/2485624/At the 2026 South Beach Symposium, Neal Bhatia, MD, FAAD, delivered a wide-ranging and opinionated overview of the current dermatology therapeutic landscape, arguing that Innovation is uneven across disease states and increasi
- Danish Registry Study Shows Rising cSCC and CIS Incidence Over 18 Yearshttps://practicaldermatology.com/news/nearly-two-decades-of-data-highlight-shifting-patterns-in-keratinocyte-neoplasms/2485635/Incidence rates of cutaneous squamous cell carcinoma (cSCC) and cSCC in situ (CIS) have continued to rise in Denmark over nearly two decades, while keratoacanthoma (KA) incidence has declined, according to a large population-based registry study.
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- Analysis: ChatGPT and DeepSeek Largely Align With Psoriasis Treatment Guidelineshttps://practicaldermatology.com/news/analysis-chatgpt-and-deepseek-largely-align-with-psoriasis-treatment-guidelines/2485578/Large language models (LLMs) ChatGPT and DeepSeek generally adhere to established psoriasis treatment guidelines, but some performance gaps remain. Investigators publishing in the Journal of Drugs in Dermatology exp